Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Renishaw FY profits seen at top end of guidance, finance director to retire

(Sharecast News) - Engineering firm Renishaw said on Thursday that full-year revenue and profits would be towards the middle and top ends of previous guidance, respectively. Renishaw said FY revenues were expected to be somewhere in the middle of its £700m to £720m guidance range, while adjusted pre-tax profits were seen at the top of forecasts of £109m to £127m.

The FTSE 250-listed firm also revealed that group finance director Allen Roberts will not stand for re-election at its upcoming annual general meeting.

Roberts will step down from the board after 46 years with Renishaw on 26 November, but will remain an employee of the group until 31 December. Renishaw added that a process to recruit a chief financial officer had already begun.

Co-founder John Deer said: "Allen has been a huge part of the Renishaw success story. From the first interactions that Sir David McMurtry and I had with him in 1974 it was clear that when the time was right for us to recruit our first finance director, Allen was the person who would help us to shape Renishaw's future.

"The company owes him an enormous debt of gratitude for helping to navigate its financial and strategic development over the past 46 years, notably in establishing its overseas subsidiaries."

As of 0825 BST, Renishaw shares were up 5.55% at 3,140p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.